Selvita initiates IND-enabling studies for its first-in-class PIM/FLT3 inhibitor
31 March 2015 | By Victoria White
Selvita announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate...
List view / Grid view
News
Invectys raises 1.7 million euros more to finance the clinical development of its therapeutic cancer vaccine
31 March 2015 | By Victoria White
Invectys has announced fundraising of 1.7 million euros from its original group of private investors, accelerating the clinical development of INVAC-1...
AstraZeneca joins Genomics England to accelerate the development of new treatments arising from the 100,000 Genomes Project
31 March 2015 | By Victoria White
AstraZeneca has joined with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project...
Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance
31 March 2015 | By Victoria White
Norvatis and Aduro have entered an alliance that is focused on the discovery of cancer immunotherapies and launched a new immuno-oncology research group...
Pfizer appoints Dr Charles Reay Mackay as Chief Scientific Officer, Inflammation and Immunology Research Unit
31 March 2015 | By Victoria White
Pfizer Inc. has announced that Charles Reay Mackay will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit...
MSD and Intrexon announce agreement for the development and commercialisation of CAR-T cancer therapy
31 March 2015 | By Victoria White
Merck Serono and Intrexon Corporation have announced an exclusive collaboration and license agreement to develop and commercialise CAR-T cancer therapies...
CRT and BioInvent expand collaboration with University of Southampton to develop new immunotherapy treatments for cancer
30 March 2015 | By Victoria White
CRT and BioInvent have announced the start of a two-year research collaboration with leading antibody researchers at the University of Southampton...
Nanoparticles could provide a new treatment option for patients with AMD
30 March 2015 | By Victoria White
Around 6.5 million Europeans currently suffer from AMD. Nanoparticles could potentially be used as carriers for drug treatments instead of injections...
MRC and UCB collaborate to offer access to UCB’s novel antibody discovery platform
30 March 2015 | By Victoria White
The MRC and UCB are to launch a collaboration that will provide scientists with access to cutting-edge technologies to discover new monoclonal antibodies...
New Abatacept trial to investigate if targeted immunotherapy can prevent rheumatoid arthritis
30 March 2015 | By Victoria White
A new trial of the drug Abatacept could bring hope to the millions of Britons who are likely to one day suffer from rheumatoid arthritis...
Cellectis announces pricing of its initial public offering of American Depositary Shares
30 March 2015 | By Victoria White
Cellectis has announced the pricing of its initial public offering of 5,500,000 ADSs at a price to the public of $41.50 per ADS...
Ebola: £1 million grant to develop ‘in the field’ test
27 March 2015 | By Victoria White
PHE scientists are heading a consortium researching a rapid ‘in the field’ Ebola test, following the successful award of IMI funding...
New role uncovered for ‘oldest’ tumour suppressor gene- the retinoblastoma gene
26 March 2015 | By Victoria White
Scientists have revealed a brand new function for one of the first cancer genes ever discovered – the retinoblastoma gene...
Taconic Biosciences and Cellaria Biosciences agree to scientific collaboration to facilitate xenograft use in oncology research
26 March 2015 | By Victoria White
Taconic and Cellaria have entered into a scientific collaboration to facilitate use of patient-derived xenografts in animal models for oncology research...
Medical breakthroughs on the horizon with £32m boost from the Biomedical Catalyst
26 March 2015 | By Victoria White
New treatments, diagnostics and medical technologies are set to benefit from an investment of £32 million through the Biomedical Catalyst...
